Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Treatment Protocol Increases Survival Of Very Young Infants With Acute Lymphoblastic Leukemia

20.07.2007
A new treatment protocol for infants under one-year with acute lymphoblastic leukaemia (ALL) has shown increased survival compared to conventional regimens. The findings are reported in an Article published in this week’s edition of The Lancet.

ALL in infants aged younger than 12 months is both rare and biologically different from ALL in older children. Although the cure rate in children with ALL has improved from around 10% 40 years ago to 80% currently, this improved cure rate has not been seen in infants under 12-months, where event-free survival (EFS) has been reported in the range 17-45%.

Dr Rob Pieters, Erasmus MC-Sophia Childrens Hospital, Rotterdam, The Netherlands and colleagues did a study of 482 infants from 22 countries aged under one-year – The Interfant-99 trial. The patients were arranged in risk-order following their peripheral blood response to a 7-day prednisone pre-treatment (prednisone is a standard ALL treatment). They were then given a hybrid treatment regimen based on the standard treatment protocol for ALL, incorporating some elements designed for treatment of acute myeloid leukaemia (AML).

With an average follow-up time of just over three years, the researchers found that 58% of patients who received the hybrid treatment were in complete remission, while at four years follow-up 47% had experienced EFS. In previous studies of ALL, EFS has been reported in the range 17-45%. The hybrid treatment protocol did not produce more toxic effects than in previous regimens. The authors say: “Patients treated with our hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL.”

The authors believe that the use of cytarabine in low-dose and high-dose sequential course could have led to the improved outcomes in Interfant-99. In-vitro studies have shown that infant lymphoblasts are highly sensitive to cytarabine.

The authors conclude: “We believe that this hybrid treatment protocol will be used as the standard for continuing international collaborative studies that aim to further improve outcomes for acute lymphoblastic leukaemia in infants.”

In an accompanying Comment, Dr Josep-Maria Ribera and Dr Albert Oriol, Institut Català d’Oncologia-Hospital Universitari Germans Trias I Pujol, Badalona, Spain, say “Despite the good results of the Interfant-99 protocol, there is a long way to go....new strategies, mainly derived from knowledge of the disease at a genomic level, are urgently needed. They will lead to the development of novel agents that will hopefully be integrated within the current cytarabine-based strategies. To achieve this goal, international collaboration must continue in this rare leukaemia.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/Lymphoblastic.pdf

More articles from Health and Medicine:

nachricht Light beam replaces blood test during heart surgery
28.02.2017 | University of Central Florida

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New technology offers fast peptide synthesis

28.02.2017 | Life Sciences

WSU research advances energy savings for oil, gas industries

28.02.2017 | Power and Electrical Engineering

Who can find the fish that makes the best sound?

28.02.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>